|
|
Blood, Vol. 113, Issue 18, 4224-4231, April 30, 2009
A TLR2 ligand suppresses inflammation by modulation of chemokine receptors and redirection of leukocyte migration
Blood McKimmie et al.
113: 4224
Supplemental materials for: McKimmie et al
Files in this Data Supplement:
- Table S1. Primer sequences (PDF, 20.4 KB)
- Figure S1 (JPG, 122 KB)
-
(A) Skin thickness of stained sections of inflamed WT skin from mice co-incidentally treated with or without BLP. Skin thickness was assessed by counting 20 fields per section with 10 skin sections per point. The graph shows mean epidermal and dermal thickness and associated standard deviations. (B) Mean and standard deviations for skin thickness of treated and untreated D6-deficient mice assessed as above. (C) Numbers of T cells and (D) mast cells in the inflamed dermis and epidermis of untreated and BLP treated D6-deficient mice counted in 10 fields-of-vision. Note that “total CD3” numbers refers to the total number of CD3 cells counted in the dermis and epidermis together. Again, the error bars represent standard deviations. (E) Mean skin thickness, and standard deviations, of TPA treated D6-deficient mice with or without therapeutic BLP. Skin thickness was quantified as described above.
- Figure S2 (JPG, 98.1 KB)
-
(A) Dose-dependent effect of BLP on CCR2 down-regulation in murine bone marrow derived macrophages and (B) TNF upregulation. Dots show the mean of two replicates ± standard deviation. (C) Viaprobe staining of BLP treated T cells, DCs, and Macrophages showing no significant induction of cell death above background.
|
|
